About Us

Stamford Therapeutics Consortium (STC) is a privately owned and operated clinical research site specializing in phase II, III, and IV clinical trials for the pharmaceutical and biotechnology industries. Operating as an independent investigational site since its founding in 1994, the company’s sole mission is to conduct the highest quality clinical trials so that new, safe and effective medications can be developed, researched and approved for a variety of indications and diseases.

STC was founded by the late Dr. Paul Dalgin, a rheumatologist, and his wife Judy with the idea that research is an important and required element for the advancement of medical science. Equally, clinical research studies can offer patients access to potentially better, more efficacious treatments. Dr. Dalgin chose the word, “Consortium” in the company’s name to reflect his desire to work closely with other like-minded physicians in the community. His goal was to conduct clinical trials across a range of medical specialties and diagnostic areas. Today, the company reflects the achievement of this objective through its working relationship with a cardiology group, a large multispecialty medical practice, and a team of physicians who serve as sub-investigators for many of its clinical trials. STC still maintains a significant presence in research for the treatment of osteoarthritis and rheumatoid arthritis, a legacy of Dr. Dalgin’s early work. At the same time, STC has continued to expand its research into new therapeutic areas, and year after year the list of specialties grows to accommodate a growing demand and new innovations in healthcare.